Diagnostic Screening Workflow for Mutations in the BRCA1 and BRCA2 Genes

Area of Science:

• Genetics
• Molecular Diagnostics
• Bioinformatics

Background:

• Screening large genes like BRCA1 and BRCA2 for mutations presents challenges in molecular diagnostics.
• Traditional Sanger sequencing is common but may not meet increasing demands efficiently or cost-effectively.
• Massively parallel sequencing (MPS) offers a scalable alternative for genetic mutation screening.

Purpose of the Study:

• To establish a streamlined workflow for amplifying and screening all coding regions of BRCA1 and BRCA2 genes.
• To evaluate a Massively Parallel Sequencing (MPS) approach using multiplex PCR and pyrosequencing for BRCA1/2 mutation detection.
• To compare the efficiency and accuracy of MPS with traditional Sanger-based sequencing.

Main Methods:

• Designed primers to amplify all coding exons of BRCA1/2, avoiding known variants to prevent allelic dropout.
• Employed a Massively Parallel Sequencing (MPS) strategy involving multiplex PCR and pyrosequencing.
• Utilized a complementary fragment analysis assay to address false positives in homopolymeric regions and filtered variants by frequency and sequence depth.

Main Results:

• Successfully achieved Sanger-based sequencing of PCR-amplified BRCA1/2 coding regions.
• The combined MPS and homopolymer protocol demonstrated 100% sensitivity and 99.5% specificity.
• BRCA1/2 mutation screening using MPS significantly reduced costs and analysis time compared to Sanger sequencing.

Conclusions:

• The MPS workflow provides a more efficient and economical alternative for BRCA1/2 gene mutation screening.
• MPS analysis yields high analytical sensitivity and specificity for genetic mutation detection.
• Complementary fragment analysis and Sanger sequencing confirmation were sometimes necessary for comprehensive MPS analysis.